Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:: WJ: Contract/grant – AstraZeneca, Janssen, and Lilly.: NE: Conference registration grants – AbbVie; speakers fees – Roche and AstraZeneca.: CPF: Consultancy and honoraria – AbbVie, Acerta Pharma/AstraZeneca, Atara Biotherapeutics, Celgene/BMS, GenMab, Gilead/Kite, Incyte, Lilly, Janssen, MorphoSys, Ono, Roche, and Takeda; research funding – BeiGene.: WT: Consultancy and honoraria – BMS, Gilead, Incyte, and Roche; travel expenses – Gilead and Takeda.: AGP: Consultancy – CellCarta; founder – Precision Assays.: JRW: Consultancy – CellCarta.: FK: Employment and stock ownership – AstraZeneca.: CW: Employment – AstraZeneca.: GP: Employment and stock ownership – AstraZeneca.: SS: Employment and stock ownership – AstraZeneca.: VM: Employment and stock ownership – AstraZeneca (a family member is an employee and stock owner of Gilead).: RM: Employment and stock ownership – AstraZeneca.: ED: Employment and stock ownership – AstraZeneca.: TM: Honoraria – AstraZeneca, Alexion, Gilead, Novartis, Roche, Janssen, AbbVie; advisory board – AstraZeneca, AbbVie, Janssen, MorphoSys, Alexion."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by AstraZeneca. Medical writing support was provided by Sarah Huh, PharmD, and Cindy Gobbel, PhD, of Peloton Advantage, LLC (Parsippany, NJ, USA), an OPEN Health company, and funded by AstraZeneca. Manuscript submission support was provided by Kelly Montenegro of Peloton Advantage, LLC, funded by AstraZeneca and authorized by the authors. Fred Hutchinson Cancer Center would like to acknowledge infrastructural funding for targeted proteomic assay analyses and part of Fred Hutchinson staff time to work on the manuscript from the National Cancer Institute (NCI) grant no. U01CA271407 (NCI Clinical Proteomic Tumor Analysis Consortium program) and grant no. R01CA235575 to AGP, and the NCI Research Specialist program (grant no. R50CA211499) to JRW."

"Registration:: NCT03328273"